TO THE EDITOR
Lymphoma-associated hemophagocytic syndrome (LAHS) is characterized by the infiltration of the bone marrow, spleen, and liver by lymphoma cells and is accompanied by an exuberant hyperplasia of hemophagocytic histiocytes. Most cases of LAHS in western countries consist of NK or T cell lymphoma and this has been believed to be one of the reasons for the poor prognosis of LAHS. 1, 2 Recently, some cases with B cell LAHS have been reported, mainly from Asian countries. 3, 4 In Japan, 68 cases of B-LAHS were included in the 142 LAHS cases according to a recent survey. 5 The clinico-pathological feature consists of fever, hepatomegaly and splenomegaly, often without associated lymphadenopathy. 4 Increased levels of lactate dehydrogenase (LDH), C-reactive protein, ferritin and soluble interleukin-2 receptor (sIL-2R) are also characteristic in these affected patients. 4 The prognosis of B-LAHS is poor with a median survival period of 9 months in the 25 reported cases in Japan, probably due to difficulties of diagnosis and the resistance of the underlying lymphoma to conventional chemotherapies. 4, 6 High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) has been accepted as one of the treatment modalities for non-Hodgkin's lymphoma (NHL), and autologous stem cell transplantation for patients with high risk NHL in complete remission showed longer survival rates as compared with those obtained with conventional chemotherapy. 7 These observations prompted us to apply PBSCT to the treatment strategy for patients with B-LAHS.
Between 1995 and 1999, five adult patients diagnosed as having B-LAHS were treated with high-dose chemotherapy followed by autologous PBSCT in Kyoto Prefectural University Hospital or its affiliated hospitals. All procedures were performed with informed consent. Four of five patients were male and ages ranged from 41 to 63 (Table 1) . At the initial presentation, all of the patients had fever, hepatosplenomegaly and cytopenia without skin or neurological symptoms and three of five patients (cases 3, 4 and 5) had lymphadenopathy. In all patients, the bone marrow showed hemophagocytosis with lymphoma cell infiltration, and increased levels of LDH, ferritin and sIL-2R were observed in the blood (data not shown). Final diagnoses of lymphoma were made by flow cytometric analysis or histological findings of biopsied lymph nodes (cases 3, 4 and 5) or the marrow (cases 1 and 2). In all cases, histology showed characteristic findings of diffuse large cell lymphoma, and immunophenotypes of the lymphoma cells were of the B cell type. Examination of patients' sera revealed no signs of active Epstein-Barr virus infection (data not shown).
After two to four courses of CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone), hemophagocytosis was resolved in all cases and remission was achieved in four of five patients (patients 2-5). Then all patients were given high-dose etoposide (500 mg/m 2 , 3 days) followed by subcutaneous administration of recombinant human granulocyte colony-stimulating factor (G-CSF, 75 g/body/day) for PBSC mobilization. PBSCs were collected during leukocyte recovery using a CS-3000 blood cell separator (Fenwal, Deerfield, IL, USA). Sufficient numbers of PBSCs could be harvested on 2 to 3 consecutive days in all patients except one (patient 4) who required another mobilization therapy consisting of high-dose cytarabine (12 g/m 2 ) and G-CSF to obtain a sufficient number of CD34 + cells for transplantation ( were detected morphologically in the marrow just before the mobilization therapy. Immunomagnetic procedures with the Baxter ISOLEX system (Baxter Healthcare, Irvine, CA, USA) were used for the enrichment. The purity of CD34 + cells harvested from patient 1 was 92.4% and the recovery rate was 43.2%. PBSC harvests were stored at −130°C.
After two or three courses of CHOP regimen following PBSC collection, all the patients were in complete remission and they received myeloablative chemotherapies followed by PBSCT as shown in Table 2 /kg) and the median numbers of days to reach neutrophil Ͼ500/l and platelet Ͼ50 000/l were 10 (range 9-12) and 20 (range 13-21), respectively. Regimen-related toxicity (RRT) included documented fever of unknown origin, stomatitis, and diarrhea; all of them were within grade III according to the World Health Organization scale and diminished soon after the appropriate therapies. At follow-up examinations of 6-32 months (median 18 months) after transplantation, all but one patient were alive and disease free. Case 2 died of a relapse 6 months after transplantation despite subsequent therapies. In case 1, the lymphoma relapsed 4 months after transplantation as a para-spinal tumor, but remission was achieved after local irradiation. Relapses in these two cases were not accompanied by hemophagocytic syndrome. This is the first report describing the safety and efficacy of auto-PBSCT in the treatment of B-LAHS. Majluf-Cruz et al 6 demonstrated that the presence of hemophagocytic syndrome (HPS) is a negative prognostic factor for patients with hematological neoplasms. Moreover, all the patients in our study belonged to the 'high' risk group according to the International Prognostic Index. Most of the reported cases with B-LAHS received PSL alone, COP or CHOP regimens and the prognoses were quite poor and the one patient who received ProMACE/CytaBOM achieved a longer survival. 4 From these observations, we started a new treatment strategy including auto-PBSCT. Preferential involvement of bone marrow by LAHS may also raise the risk of lymphoma cell contamination of the autograft. Unfortunately, we did not check the minimal residual disease in the graft. However, PBSC collection by high-dose etoposide after induction and consolidation by a CHOP regimen was successful in our study and CD34 + cell selection may improve the quality of autografts in patients with LAHS.
Myeloablative high-dose chemotherapies followed by PBSCT could be safely performed without any severe RRT and the survival of the present studied cases seemed to be longer than the survivals in previously reported cases. 4, 6 This is probably due to the consecutive intensive chemotherapies and the myeloablative conditioning regimen overcoming the resistance of residual malignant clones. Recently, allogeneic bone marrow transplantation has been performed for pediatric patients with HPS. 8 but in adult cases, the affected patients are often too old to receive allogeneic stem cell transplantation safely and an HLA-matched donor is not easily available at the appropriate time. Although the number of studied cases is too small and the follow-up period is too short to determine the efficacy of PBSCT on LAHS, the safety and the efficacy verified in this study encourage us to plan a larger scale study. On the other hand, the poor CR, complete remission; MCNU, ranimustine; CPM, cyclophosphamide; CBDCA, carboplatin; BU, busulfan; VP16, etoposide; Ara-C, cytarabine; neut, neutrophil; Plt, platelet. a The lymphoma relapsed 4 months after transplantation as a para-spinal tumor, but remission was achieved after local irradiation. b Died of a relapse 6 months after transplantation. Relapses in these two cases were not accompanied by hemophagocytic syndrome.
Leukemia
prognosis of LAHS is partly associated with the difficulties of diagnosis resulting in the delay of therapy and organ failure by cytokine storm, because LAHS is not always accompanied by marked lymphadenopathy. 1 Besides the appropriate therapies, a rigorous search for the underlying disease, especially for lymphoma, is important after having made the diagnosis of HPS. 
